
## Pedro LÃ<sup>3</sup>pez-Romero

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1948169/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet, The, 2018, 391, 230-240.	13.7	373
2	Effects of Teriparatide Compared with Risedronate on the Risk of Fractures in Subgroups of Postmenopausal Women with Severe Osteoporosis: The VERO Trial. Journal of Bone and Mineral Research, 2018, 33, 783-794.	2.8	84
3	Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study. Clinical Rheumatology, 2018, 37, 2381-2390.	2.2	26
4	Efficacy of teriparatide compared with risedronate on FRAX®-defined major osteoporotic fractures: results of the VERO clinical trial. Osteoporosis International, 2020, 31, 1935-1942.	3.1	12
5	Psychotropic medications and proton pump inhibitors and the risk of fractures in the teriparatide versus risedronate VERO clinical trial. Bone, 2020, 130, 115113.	2.9	7
6	Attention-deficit/hyperactivity disorder Under Treatment Outcomes Research (AUTOR): a European observational study in pediatric subjects. ADHD Attention Deficit and Hyperactivity Disorders, 2015, 7, 295-311.	1.7	5
7	Distribution of Prevalent and Incident Vertebral Fractures and Their Association with Bone Mineral Density in Postmenopausal Women in the Teriparatide Versus Risedronate VERO Clinical Trial. Calcified Tissue International, 2020, 106, 646-654.	3.1	5
8	Baricitinib further enhances disease-modifying effects by uncoupling the link between disease activity and joint structural progression in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2022, 81, 622-631.	0.9	4
9	SAT0102â€ASSOCIATION BETWEEN BASELINE HAEMOGLOBIN LEVELS AND RADIOGRAPHIC JOINT DAMAGE PROGRESSION IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH BARICITINIB OR STANDARD OF CARE. , 2019, , .		1
10	Assessment of the association of baseline anti-CarbV and anti-MCV antibodies with response to treatment and radiographic progression in an RA population treated with either methotrexate or baricitinib: post-hoc analyses from RA-BEGIN. Arthritis Research and Therapy, 2020, 22, 193.	3.5	1